Oral News and Research

RSS

Teva Pharmaceuticals sells 31 generic drug products to ANI Pharmaceuticals

ANI Pharmaceuticals, Inc., an emerging generic pharmaceutical company, today announced that it has acquired 31 previously marketed generic drug products from Teva Pharmaceuticals for $12.5 million in cash and a percentage of future gross profits from product sales.

27 Dec 2013

Surgery offers better survival, functional outcomes than chemotherapy for patients with tongue cancer

Patients with tongue cancer who started their treatment with a course of chemotherapy fared significantly worse than patients who received surgery first, according to a new study from researchers at the University of Michigan Comprehensive Cancer Center.

27 Dec 2013

Oramed Pharmaceuticals to purchase $15,800,000 shares in registered direct offering

Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, today announced that it has entered into definitive agreements with investors to purchase an aggregate of 1,580,000 shares of common stock at a price of $10.00 per share in a registered direct offering.

26 Dec 2013

Planmeca to co-develop CAD/CAM products with E4D Technologies

Planmeca, the world's largest privately owned dental imaging company and equipment manufacturer, announced today that it has made a non-controlling, strategic investment in E4D Technologies, LLC, developer of the E4D CAD/CAM Restorative System. This strategic investment reinforces Planmeca's on-going commitment to help dental providers improve patient care by offering a comprehensive portfolio of integrated digital dental solutions for dentists and dental laboratories.

24 Dec 2013

Inosine drug raises blood and cerebrospinal fluid urate levels in Parkinson disease patients

The drug inosine appears to be a safe and effective way to raise blood and cerebrospinal fluid urate levels in patients with early Parkinson disease, suggesting it may be a potential strategy to slow the disability progression of the degenerative neurological disorder, according to a report published by JAMA Neurology, a JAMA Network publication.

23 Dec 2013

FDA grants QIDP and Fast Track designations to TaiGen's nemonoxacin

TaiGen Biotechnology Company, Limited today announced that the U.S. Food and Drug Administration has granted nemonoxacin (Taigexyn) Qualified Infectious Disease Product and Fast Track designations for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.

23 Dec 2013

Real and sham weekly acupuncture treatments ease hot flashes of anticancer drug treatment

Both real and sham weekly acupuncture treatments eased hot flashes and other side effects of anticancer drug treatment in a small, preliminary study of breast cancer patients, Baltimore researchers have found.

23 Dec 2013

Researchers compare prescription drug costs between the U.S. and the U.K

The 2009 costs of antibiotics covered by private insurance companies in the U.S. for children younger than 10 years old were estimated to be more than five times higher than the costs in the United Kingdom (U.K.), which are covered by a government universal health plan.

23 Dec 2013

Oramed reports positive results from ORMD-0801 pharmacokinetic study in type 1 diabetes patients

Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today successful results in a clinical trial testing the pharmacokinetic dose response of its oral insulin capsule (ORMD-0801) in type 1 diabetes patients.

20 Dec 2013

ESC presents results of pilot registry on management and treatment of AF in Europe

Results for a pilot registry on the management and treatment of atrial fibrillation in Europe were presented yesterday by the European Society of Cardiology. AF is the commonest cardiac rhythm disorder and each of us have a one-in-four lifetime risk of developing it. Statistics show that oral anticoagulant use has increased, but new oral anticoagulant use is still low. Authors also concluded that compliance with treatment guidelines for patients with the lowest and higher stroke risk scores remains suboptimal.

20 Dec 2013

State highlights: Calif. midwives prepare for new independence; Minn. gov supports nurse board changes; Colo. Medicaid dental care

California licensed midwives will have increased independence and authority in attending births, potentially giving more pregnant women access to their services under a new law that goes into effect in January. Assembly Bill 1308 removes an unworkable clause that required all licensed midwives to be supervised by a physician. Licensed midwives had been unable to fulfill that requirement since it went into effect 20 years ago because physicians' malpractice insurance prohibited them from filling that role. In addition, licensed midwives will now be authorized to operate birth centers without physician supervision and will have increased access to drugs, tests and medical devices used in their practice (Renner, 12/18).

20 Dec 2013

New research assesses nanomedicine-based approaches for treating cancer

As cancer maintains its standing as the second leading cause of death in the U.S., researchers have continued their quest for safer and more effective treatments. Among the most promising advances has been the rise of nanomedicine, the application of tiny materials and devices whose sizes are measured in the billionths of a meter to detect, diagnose and treat disease.

20 Dec 2013

Researchers develop oral vaccine against Helicobacter pylori

Researchers from Southern Medical University in Guangdong, Guangzhou, China, have developed an oral vaccine against Helicobacter pylori, the bacteria responsible for peptic ulcers and some forms of gastric cancer, and have successfully tested it in mice. The research is published ahead of print in the journal Clinical and Vaccine Immunology.

20 Dec 2013

Takeda to acquire exclusive license to develop Natrogen's Natura-alpha compound

Takeda Pharmaceutical Company Limited and Natrogen Therapeutics International, Inc. jointly announced today an agreement whereby Takeda will acquire an exclusive license to develop Natrogen's Natura-alpha compound as well as an option to acquire Natrogen. Natura-alpha is a synthetic small molecule oral compound that is believed to inhibit pro-inflammatory cytokine expression, which may help to reduce gastrointestinal inflammation. Natura-alpha is currently in Phase 2 development for the treatment of ulcerative colitis.

20 Dec 2013

BeiGene doses first patient in Phase 1 study of BGB-283

BeiGene (Beijing), Co., Ltd., today announced dose administration for the first patient in a Phase 1 study of BGB-283 in patients with B-RAF or K-RAS mutations. BGB-283 is an investigational, oral, selective, potent second generation inhibitor of B-RAF, making it a targeted therapeutic candidate to potentially treat and bring benefit to patients with cancers that harbor BRAF mutations and/or aberrations in the RAS-MAPK (mitogen-activated protein kinase) pathway.

20 Dec 2013

Shades of gray in QoL measures after dental whitening

A complex picture has emerged of changes in oral-health-related quality of life after at-home dental bleaching, with some measures improving and others deteriorating after the treatment, a Brazilian double-blind randomized clinical trial has shown.

19 Dec 2013

Daiichi Sankyo submits LIXIANA supplemental NDA for review in Japan

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has submitted a supplemental New Drug Application for its oral, once-daily direct factor Xa-inhibitor LIXIANA® (Edoxaban Tosilate Hydrate) for review by the Japanese Ministry of Health, Labour and Welfare. Daiichi Sankyo is seeking approval in Japan for edoxaban in new indications for non-valvular atrial fibrillation and symptomatic venous thromboembolism.

19 Dec 2013

Researchers use 3D technology from film industry to analyze rehabilitation for stroke patients

Researchers in Gothenburg have been using 3D technology from the film industry to analyze the everyday movements of stroke patients. The results, which are reported in a doctoral thesis at the Sahlgrenska Academy, indicate that computerized motion analysis increases our knowledge of how stroke patients can improve their ability to move through rehabilitation.

19 Dec 2013

Oral garlic tablets shows no effect in clearing vaginal thrush, says study

Led by University of Melbourne PhD candidate Cathy Watson also of the Royal Women's Hospital, the findings were published online in the British Journal of Obstetrics and Gynaecology.

18 Dec 2013

Arizona scientists investigate intriguing effects of spaceflight on microbial pathogens

At Arizona State University's Biodesign Institute, Cheryl Nickerson and her team have been investigating the intriguing effects of spaceflight on microbial pathogens.

17 Dec 2013

Oral News and Research

Teva Pharmaceuticals sells 31 generic drug products to ANI Pharmaceuticals

Surgery offers better survival, functional outcomes than chemotherapy for patients with tongue cancer

Oramed Pharmaceuticals to purchase $15,800,000 shares in registered direct offering

Planmeca to co-develop CAD/CAM products with E4D Technologies

Inosine drug raises blood and cerebrospinal fluid urate levels in Parkinson disease patients

FDA grants QIDP and Fast Track designations to TaiGen's nemonoxacin

Real and sham weekly acupuncture treatments ease hot flashes of anticancer drug treatment

Researchers compare prescription drug costs between the U.S. and the U.K

Oramed reports positive results from ORMD-0801 pharmacokinetic study in type 1 diabetes patients

ESC presents results of pilot registry on management and treatment of AF in Europe

State highlights: Calif. midwives prepare for new independence; Minn. gov supports nurse board changes; Colo. Medicaid dental care

New research assesses nanomedicine-based approaches for treating cancer

Researchers develop oral vaccine against Helicobacter pylori

Takeda to acquire exclusive license to develop Natrogen's Natura-alpha compound

BeiGene doses first patient in Phase 1 study of BGB-283

Shades of gray in QoL measures after dental whitening

Daiichi Sankyo submits LIXIANA supplemental NDA for review in Japan

Researchers use 3D technology from film industry to analyze rehabilitation for stroke patients

Oral garlic tablets shows no effect in clearing vaginal thrush, says study

Arizona scientists investigate intriguing effects of spaceflight on microbial pathogens

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News